Drugs / Staloral Birch
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00932607 | Jul 2009 → Feb 2010 | seasonal allergic rhinitis | HAL Allergy | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05668390 | Sep 2023 → Aug 2025 | allergic disease | Stallergenes Greer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Staloral Birch | “Objective of the study is to show, on an exploratory basis, that treatment with SUBLIVAC Birch is also effective compared to treatment with Staloral Birch by means of reduction...” NCT00932607 ↗ |
| Route | Other | “Route of administration: Sublingual application.” NCT00932607 ↗ |